ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Is there a link between multiple sclerosis and Alzheimer disease? A critical note.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) and Alzheimer disease (AD) are two neurological disorders that represent a major health problem, as they pose an enormous burden to the patients' quality of life. Although no cure is available, due to recent therapeutic advancements that significantly extend the lifespan, increased prevalence of AD is seen in elderly MS patients. Although cognitive dysfunction affects 40-60% of people with MS, little is known about the co-occurrence of these two conditions and their pathogenetic relationship. About 125 cases of comorbid MS and AD necessitate an evaluation of the literature on the overlaps between AD and MS. Although the etiology of both disorders is unknown, with the emerging recognition that demyelination plays a role in the risk and progression of AD, it has been proposed that both MS and AD share genetic and environmental factors inducing immune cell dysfunctions, inflammation, and neurodegeneration. These mechanisms may be triggered by an early viral infection, Epstein-Barr virus infection being a major risk factor. Both MS and AD show signs of amyloid pathology in the brain and impaired Aβ metabolism in CSF, suggesting overlapping pathobiology. Recent studies revealed similar polygenicity of AD and MS, providing molecular genetic insight into the immune mechanisms involved in both diseases, with similar patterns of microglial activation promoting neuroinflammation. The accumulating damage leads to demyelination, amyloid dysfunction, and damaged blood-brain barrier, together with mitochondrial impairment and other molecular mechanisms leading to neurodegeneration and development of dementia later in life. This short review highlights the overlapping pathophysiological processes promoting the development of AD pathology in progressed MS.
Indexed as
Identifiers
41428075What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.